DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the 3B BLACKBIO DX LTD. (3BBLACKBIO) share price today?

3B BLACKBIO DX LTD. (3BBLACKBIO) is trading at ₹1,250.4 on the NSE, down 1.43% on the day. Source: DocStoX.

What is the PE ratio of 3B BLACKBIO DX LTD.?

3B BLACKBIO DX LTD. has a price-to-earnings (PE) ratio of 18.3 in the Healthcare sector.

What is the market capitalisation of 3B BLACKBIO DX LTD.?

3B BLACKBIO DX LTD. has a market capitalisation of approximately ₹1,083 crore.

3B BLACKBIO DX LTD.

3BBLACKBIO·NSE·Healthcare

₹1,250.40▼ -18.10 (-1.43%)

Healthcare · Healthcare Services

Revenue compounding 32% a year

Day₹1240.00

₹1276.10

52W₹1085

₹144246%

Open

₹1269.30

High

₹1276.10

Low

₹1240.00

Prev Close

₹1268.50

Volume

18.2K

VWAP

₹1254.72

Snapshot

Key fundamentals

Market Cap

₹1,083 Cr

P/E Ratio

18.32Fair

P/B Ratio

3.19

EPS

₹68.27

Book Value

₹378.00

ROE

19.80%Strong

ROCE

25.00%Efficient

Dividend Yield

N/A

Debt / Equity

N/A

Face Value

₹10.00

52W High

₹1441.50

52W Low

₹1085.00

Sector

Healthcare

Industry

Healthcare Services

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹558

▼ 55.4%downside

Trading at ₹1,250 — 55% above our estimate

BearFair valueBull

₹474₹558₹762

/100

Business quality — Solid

Growth 100Profitability 87Efficiency 43Valuation 79

Plain English

Our view

Revenue compounding 32% a year
Capital is working hard (ROCE 25%)
Fundamental red flags (Piotroski 3/9)

Strengths

Capital is working hard (ROCE 25%)
Revenue compounding 32% over 3 years
Profit growing 32% a year

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

20% ROE fading to 13% over ~10 yrs, on ₹378 book

₹501

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹762

Analyst target

No analyst coverage

—

Blended fair value₹558

What the numbers say

Investment thesis

Bull case

Capital is working hard (ROCE 25%)
Revenue compounding 32% over 3 years
Profit growing 32% a year

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

18.3Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

19.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

25.0%Efficient

Above 18% means capital is working hard

Debt/Eq

—

Mkt Cap

₹1,083 Cr

P/B

3.19

EPS

₹68.27

Div Yield

—

What changed

Recent changes

Domestic institutions+0.2% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 18.3×

Growth

Strong

+32% rev CAGR

Profitability

Excellent

19.8% ROE

Financial health

N/A

No debt data

Momentum

N/A

No technicals

Today

Trading activity

Delivery %65.8%

Turnover₹228.75L Cr

Trades1,190

VWAP₹1254.72

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+31.8%

-9.0%

10Y

+23.6%

Profit

+32.1%

-12.1%

10Y

—

EPS

+25.5%

-14.8%

10Y

+63.2%

Profile

Pros

Company is almost debt free.
Company is expected to give good quarter
Company's median sales growth is 21.9% of last 10 years

Watch-outs

Cons

Earnings include an other income of Rs.25.6 Cr.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Domestic institutions added 0.17 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

41%

Promoter

Promoters

41.0%+0.01

Public

54.4%-0.10

FII / FPI

2.5%-0.07

DII

2.1%+0.17

Quarterly trend

Ownership over time

Q1 FY27

Promoter40.95%

FII2.50%

DII2.15%

Public54.40%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]